Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Clinical Oncology

• Publication date

  2018-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2018.36.15_SUPPL.9537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma

  2019cites this paper
• Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.

  2019cites this paper
• Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma

  2019cites this paper
• Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches

  2018cites this paper
• Product review: avelumab, an anti-PD-L1 antibody

  2018cites this paper